Why ClearPath Is Safer for the Orbit and Skull Base

Why ClearPath Is Designed to Direct Force Near the Orbit and Anterior Skull Base—and What That Does Not Prove

Complications involving the orbit (eye socket) or the anterior skull base (the bony “ceiling” above the nasal cavity) are rare in septal procedures—but they matter because these structures sit close to where ENTs work. If you’re researching whether ClearPath may be safer for the orbit and skull base, it helps to separate design intent from what has actually been shown in studies.

This article explains why the ClearPath device is designed to control the direction of force, what published studies suggest, and what the current research does not prove. It’s educational, not medical advice.

What you’ll learn:

- What the orbit and anterior skull base are (in plain language)

- Why balloon “drift” could matter in tight nasal spaces

- What ClearPath’s guide spatula is intended to do

- What one clinical series reported—and its limits

Citations: Dillard et al., 2026 (1); URF benchtop study (2)

The Orbit and Anterior Skull Base: Why Surgeons Take Extra Precautions

What “orbit” means (and what’s nearby)

The orbit is the bony socket that surrounds and protects your eye. Although the orbit is not inside your nose, parts of the nasal cavity sit near thin bony boundaries and connected spaces in the face. That’s why nasal procedures emphasize where pressure is applied and how instruments move—especially in narrow corridors where millimeters matter.

When people worry about orbital injury risk, they’re usually thinking about force being transmitted in an unintended direction—particularly in tight, angled anatomy where a tool can shift if it isn’t well controlled. These events are uncommon, but modern septal techniques aim to make unintended direction less likely.

A helpful mental model: if the nasal passage is a hallway, the orbit is a room next door. You’re not operating in that room—but you still want your “push” to stay aimed down the hallway, not at the wall.

What “anterior skull base” means (and why it matters)

The anterior skull base is the bony “ceiling” above the nasal cavity. Above that are important structures, so surgeons avoid applying force upward or in unstable directions. Concerns here are often described as skull-base injury risk.

These complications are rare, but because the structures are sensitive, careful ENT technique emphasizes control, visualization, and predictable force. In practical terms, that means choosing tools and approaches that help keep pressure directed exactly where it’s intended, rather than letting anatomy “steer” the force.

Why “rare” still deserves attention

Even when something is unlikely, patients want to know what’s being done to keep it that way. Near the orbit and anterior skull base, the safety conversation is often about engineering plus technique: how a device behaves, how it’s guided, and how predictable its forces are in real anatomy.

—In short: proximity to sensitive structures makes controlled, directional force a reasonable design goal, even when serious complications are uncommon.

The Core Safety Idea: Directing Force Where It’s Needed

How ClearPath is designed to apply force in one direction

ClearPath is a force-directed balloon system with a balloon positioned on one side of a guide spatula. In patient-friendly terms:

- The balloon is placed so it can press on the targeted part of the septum

- The guide spatula sits alongside it and is intended to constrain where the balloon expands

- The goal is to apply pressure in a controlled, planned direction, rather than allowing expansion forces to spread unpredictably

If you like analogies, think of inflating a small air cushion: it will expand where there’s room. A guiding surface functions like a “backstop,” encouraging the expansion to push where you want it to push.

This is a design rationale that may support balloon-assisted septoplasty safety considerations, but it is not a guarantee that injuries cannot happen. Real-world outcomes still depend on anatomy, visualization, technique, and clinical judgment. (5,1)

For a deeper explanation of the concept, see directional force vs general expansion:

https://www.clearpathnasal.com/blog/why-directional-force-is-safer-than-general-expansion

—In short: ClearPath is designed to direct force using a guide spatula and one-sided balloon, which may help keep pressure aligned with the surgical plan.

Why “directional” pressure could matter near sensitive anatomy

When any balloon expands in a confined space, it will push outward—sometimes in more than one direction. ClearPath’s approach is intended to help limit unintended lateral movement, which is why some clinicians and patients explore whether a guided system may be safer near the orbit and anterior skull base.

Careful wording is important: ClearPath is designed to guide pressure where it’s needed and may help reduce movement in unintended directions. That is different from proving it prevents every complication. (5)

What Research Says About Balloon Movement (and Why Guidance Matters)

What a benchtop study found about unguided balloon drift

A laboratory (benchtop) study examined how an unguided balloon can behave between two surfaces that aren’t perfectly parallel. In plain terms, the study reported:

- If the two surfaces diverge by about 5° or more, an unguided balloon can move toward the wider gap

- That movement was greater in narrower spaces

A simple analogy: place a round object between two boards that form a slight “V.” When pressure increases, the object tends to migrate toward the side with more room. The benchtop findings don’t claim this always happens in patients—but they do provide a mechanical explanation for why “drift” can occur. This supports the idea that guidance and constraint could be valuable—especially in tight or angled anatomy. (2)

For more on this design goal, see how ClearPath is intended to limit balloon slippage:

https://www.clearpathnasal.com/blog/safety-first-how-clearpath-prevents-balloon-slippage

Important limitation: a benchtop study isn’t the same as patient outcomes

A benchtop model is not living anatomy. It can’t recreate:

- Individual differences in cartilage and bone

- Endoscopic visualization and surgical technique

- Tissue flexibility, scarring, or prior surgery

It also doesn’t answer the patient-level question: whether a guided system results in fewer rare complications (like orbit or skull-base injury) across diverse populations. The study does not provide a head-to-head clinical comparison showing that ClearPath reduces orbital or skull-base injury risk versus other approaches; it’s a mechanistic analysis only. (2)

—In short: the bench data explain why unguided balloons can drift, but they do not prove patient safety advantages.

What a ClearPath Clinical Series Reported (and What It Can’t Prove)

Safety outcomes reported in 107 patients

A retrospective series described outcomes for 107 consecutive patients who underwent ClearPath-assisted septoplasty. The authors reported no orbital injuries and no major complications as described in the manuscript. They also did not report events such as septal perforation, septal hematoma, mucosal injury, infection, synechia, or conversion to traditional septoplasty, based on their chart review. (1)

Two important caveats:

- Zero events in a series of 107 cannot rule out rare harms, especially without a control group

- The paper did not directly evaluate “skull-base protection” as a specific endpoint; absence of reported cases does not prove prevention

—In short: none were documented in this uncontrolled series, but that does not establish comparative safety.

Effectiveness signals (briefly) that support careful technique—but are not proof

- 23/107 patients had paired CT scans; the authors reported improved symmetry at measured landmarks, including a 45% mean symmetry improvement at the point of maximal deviation (definition per the paper’s method) (1)

- 43/107 patients completed SNOT-22 at 1 month; the mean score improved from 58.7 to 44.8 (p = 0.02) (1)

Context to avoid over-reading:

- The CT finding reflects a subset (about one-fifth of the series)

- The symptom follow-up also reflects a subset (about two-fifths of the series)

- Without a control group, these data do not prove effectiveness or safety

—In short: early signals are encouraging for selected patients, but they are incomplete and not definitive.

FDA Clearance: What It Covers (and What It Doesn’t)

What the cleared indication says

ClearPath is an FDA-cleared nasal balloon catheter. The 510(k) summary describes its intended use in terms of increasing intranasal space and temporarily addressing nasal obstruction, including displacement of the inferior turbinate and lower septum. (3)

This anchors the discussion in what the device is cleared to do: address obstruction by creating space intranasally—not to make claims about orbit or skull-base protection.

For background, see what FDA clearance means (and what it doesn’t):

https://www.clearpathnasal.com/blog/fda-clearance-what-it-means-for-clearpath

What FDA clearance does not claim

FDA clearance is not a guarantee of a specific outcome, especially for rare events. The cleared indication does not state that the device prevents injuries to the orbit or anterior skull base. (3,4)

—In short: clearance covers intended use for nasal obstruction and intranasal space; it does not establish comparative safety for orbit or skull base.

Who Might (and Might Not) Be a Good Fit for ClearPath

When a force-directed balloon approach may be considered

In general terms, ClearPath may be considered when nasal obstruction relates to deviation affecting the lower septum/intranasal space—aligning with the device’s cleared use and force-direction concept. Patient selection and technique remain the domain of an ENT evaluation. (3,5)

Learn more about who is a good candidate for balloon septoplasty:

https://www.clearpathnasal.com/blog/best-candidates-for-balloon-septoplasty-with-clearpath

When other approaches may still be needed

The retrospective manuscript notes that the device does not address every type of septal deformity. For example, prominent septal spurs and some cartilaginous deformities may require different or additional techniques, per the authors’ description. (1) The right plan depends on the type and location of the deviation, and on shared decision-making with an ENT.

—In short: candidacy is anatomy-specific; some deviations require other or additional methods.

Questions to Ask Your ENT About Orbit/Skull-Base Safety

Procedure planning questions

- How do you control where force is applied during septal correction?

- What visualization (endoscopy, imaging, other tools) do you use during the procedure?

- Based on my anatomy, which risks matter most—including those related to the orbit and anterior skull base?

Outcome and follow-up questions

- What symptoms should prompt an urgent call after the procedure?

- How do you monitor for complications during recovery, and what follow-up do you recommend?

A ClearPath-specific question (to compare options)

- Am I a candidate for ClearPath as an alternative to traditional septoplasty, and why or why not?

Takeaway: A Directional-Force Design With Honest Limits

- ClearPath is a device designed to direct force using a guide spatula and a one-sided balloon, which is intended to keep pressure more controlled and directional. (5)

- Lab research shows unguided balloons can drift under certain angles and in tight spaces—a mechanical reason guidance may matter. (2)

- A single-center, retrospective series of 107 patients reported no orbital injuries and no major complications as described by the authors, but it cannot prove that ClearPath is safer than other techniques or that it prevents anterior skull-base injury. (1)

- FDA clearance addresses intranasal space and obstruction; it does not constitute a skull-base or orbit protection claim. (3)

—In short: ClearPath’s directional-force design may help surgeons control where pressure goes, but current evidence does not prove comparative safety for the orbit or anterior skull base.

References

1. Dillard J, Koudouovoh C, Lee V, Barnes C, Su R, Fortson JK. Outcomes of force-directed balloon-assisted endoscopic septoplasty: a retrospective analysis with a new technique and device. Rhinology Online. 2026;9:18–23. https://www.rhinologyonline.org/Rhinology_online_issues/manuscript_2530.pdf

2. Balloon Dilation in Septal Surgery: An Experimental Analysis of Unguided Balloon Motion. URF Publishers. https://urfpublishers.com/journal/case-reports/article/view/balloon-dilation-in-septal-surgery-an-experimental-analysis-of-unguided-balloon-motion

3. FDA 510(k) Summary: Dillard Nasal Balloon Catheter (K181546). 2020. https://www.accessdata.fda.gov/cdrh_docs/pdf18/K181546.pdf

4. Brenner MJ, et al. New Medical Device and Therapeutic Approvals in Otolaryngology: State of the Art Review 2020. OTO Open. 2021. https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/10.1177/2473974X211057035

5. ClearPath Nasal Balloon System – For Physicians. https://www.clearpathnasal.com/for-physicians

This article is for educational purposes only and is not medical advice. Please consult a qualified healthcare provider for diagnosis and treatment.